ArticleJournal of medicinal chemistry2018
In Vitro and in Vivo Evaluation of
Abstract read
In one paragraph
Article in Journal of medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Article
- PET Molecular Imaging of the Endocannabinoid System in Psychiatric Disorders.Neuroscience bulletin · 2026Review
- Development of a novelActa pharmaceutica Sinica. B · 2025Article
- Imaging poly(ADP-ribose) polymerase-1 (PARP1)Acta pharmaceutica Sinica. B · 2025Article
- Development and Preclinical Characterization of [Journal of medicinal chemistry · 2025Article
- Promising Inhibitors of Endocannabinoid Degrading Enzymes Sharing a Carbamate Scaffold.Mini reviews in medicinal chemistry · 2025Review
- Recent Progress in Synthetic Applications of Hypervalent Iodine(III) Reagents.Chemical reviews · 2024Review
- Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2).Journal of medicinal chemistry · 2024Article
- Potential forBrain communications · 2024Article
- Radiochemistry for positron emission tomography.Nature communications · 2023Review
- Evaluation of [Pharmaceuticals (Basel, Switzerland) · 2023Article
- A novel monoacylglycerol lipase-targetedActa pharmacologica Sinica · 2022Article
- Imaging of Transmembrane AMPA Receptor Regulatory Proteins by Positron Emission Tomography.Journal of medicinal chemistry · 2022Article
- Target occupancy study and whole-body dosimetry with a MAGL PET ligand [EJNMMI research · 2022Article
- Development of a triazolobenzodiazepine-based PET probe for subtype-selective vasopressin 1A receptor imaging.Pharmacological research · 2021Article
- Novel Reversible-Binding PET Ligands for Imaging Monoacylglycerol Lipase Based on the Piperazinyl Azetidine Scaffold.Journal of medicinal chemistry · 2021Article
- Development of a highly-specificActa pharmaceutica Sinica. B · 2021Article
- Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development.Journal of medicinal chemistry · 2021Review
- 2-Arachidonoylglycerol Modulation of Anxiety and Stress Adaptation: From Grass Roots to Novel Therapeutics.Biological psychiatry · 2020Review
- Role of Nuclear Imaging to Understand the Neural Substrates of Brain Disorders in Laboratory Animals: Current Status and Future Prospects.Frontiers in behavioral neuroscience · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Ran ChengDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology , Massachusetts General Hospital and Harvard Medical School , Boston , Massachusetts 02114 , United States.
Wakana MoriDepartment of Radiopharmaceuticals Development , National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555 , Japan.
Longle MaDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology , Massachusetts General Hospital and Harvard Medical School , Boston , Massachusetts 02114 , United States.ORCID 0000-0002-6359-4702
Mireille AlhouayekDepartment of Pharmacology and Clinical Neuroscience , Umeå University , SE-901 87 Umeå , Sweden.
Akiko HatoriDepartment of Radiopharmaceuticals Development , National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555 , Japan.
Yiding ZhangDepartment of Radiopharmaceuticals Development , National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555 , Japan.
Daisuke OgasawaraThe Skaggs Institute for Chemical Biology and Department of Chemical Physiology , The Scripps Research Institute , SR107 10550 North Torrey Pines Road , La Jolla , California 92037 , United States.
Gengyang YuanDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology , Massachusetts General Hospital and Harvard Medical School , Boston , Massachusetts 02114 , United States.
Zhen ChenDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology , Massachusetts General Hospital and Harvard Medical School , Boston , Massachusetts 02114 , United States.
Xiaofei ZhangDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology , Massachusetts General Hospital and Harvard Medical School , Boston , Massachusetts 02114 , United States.
Hang ShiDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology , Massachusetts General Hospital and Harvard Medical School , Boston , Massachusetts 02114 , United States.
Tomoteru YamasakiDepartment of Radiopharmaceuticals Development , National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555 , Japan.
Lin XieDepartment of Radiopharmaceuticals Development , National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555 , Japan.
Katsushi KumataDepartment of Radiopharmaceuticals Development , National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555 , Japan.
Masayuki FujinagaDepartment of Radiopharmaceuticals Development , National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555 , Japan.
Yuji NagaiDepartment of Functional Brain Imaging Research , National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555 , Japan.
Takafumi MinamimotoDepartment of Functional Brain Imaging Research , National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555 , Japan.
Mona SvenssonDepartment of Pharmacology and Clinical Neuroscience , Umeå University , SE-901 87 Umeå , Sweden.
Lu WangDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology , Massachusetts General Hospital and Harvard Medical School , Boston , Massachusetts 02114 , United States.
Yunfei DuSchool of Pharmaceutical Science and Technology , Tianjin University , 92 Weijin Road, Nankai District , Tianjin 300072 , China.ORCID 0000-0002-0213-2854
Mary Jo OndrechenDepartment of Chemistry and Chemical Biology , Northeastern University , 360 Huntington Avenue , Boston , Massachusetts 02115 , United States.
Neil VasdevDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology , Massachusetts General Hospital and Harvard Medical School , Boston , Massachusetts 02114 , United States.ORCID 0000-0002-2087-5125
Benjamin F CravattThe Skaggs Institute for Chemical Biology and Department of Chemical Physiology , The Scripps Research Institute , SR107 10550 North Torrey Pines Road , La Jolla , California 92037 , United States.ORCID 0000-0001-5330-3492
Christopher FowlerDepartment of Pharmacology and Clinical Neuroscience , Umeå University , SE-901 87 Umeå , Sweden.
Ming-Rong ZhangDepartment of Radiopharmaceuticals Development , National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555 , Japan.ORCID 0000-0002-3001-9605
Steven H LiangDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology , Massachusetts General Hospital and Harvard Medical School , Boston , Massachusetts 02114 , United States.ORCID 0000-0003-1413-6315
Funding
CHEMOPROTEOMIC METHODS FOR SERINE HYDROLASE INHIBITOR DEVELOPMENTR01DA033760 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F, SCAMPAVIA, LOUIS DANIEL · 2012 to 2021
$5.1MTranslation of tau-selective PET radiopharmaceuticals in Alzheimers patientsR01AG052414 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI PRICE, JULIE C, VASDEV, NEIL · 2018 to 2021
$2.7MNeuro-PET Radiotracer Discovery for Imaging Glycogen Synthase Kinase-3R01AG054473 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI VASDEV, NEIL · 2017 to 2020
$1.7MNew PET tracers for neuroimaging of FAAH in endocannabinoid signalingK01DA038000 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2014 to 2018
$927kNovel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid SignalingR33DA043507 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2019 to 2021
$851kNovel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid SignalingR21DA043507 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2017 to 2018
$425kNIA NIH HHS R01 AG052414NIA NIH HHS R01 AG054473NIDA NIH HHS K01 DA038000NIDA NIH HHS R01 DA033760NIDA NIH HHS R21 DA043507NIDA NIH HHS R33 DA043507
Abstract
Monoacylglycerol lipase (MAGL) is the principle enzyme for metabolizing endogenous cannabinoid ligand 2-arachidonoyglycerol (2-AG). Blockade of MAGL increases 2-AG levels, resulting in subsequent activation of the endocannabinoid system, and has emerged as a novel therapeutic strategy to treat drug addiction, inflammation, and neurodegenerative diseases. Herein we report a new series of MAGL inhibitors, which were radiolabeled by site-specific labeling technologies, including
Indexed as
AnimalsAzetidinesBrainCarbon RadioisotopesFluorine RadioisotopesMacaca mulattaMaleMiceMonoacylglycerol LipasesPositron-Emission TomographyRadioactive TracersRadiopharmaceuticalsRatsRats, Sprague-DawleySubstrate SpecificityTissue DistributionAzetidinesCarbon RadioisotopesFluorine RadioisotopesMonoacylglycerol LipasesRadioactive TracersRadiopharmaceuticals
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.